What is Applied Stemcell?
Applied Stemcell operates as a premier Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO), specializing in the high-growth fields of cell and gene therapy. The company distinguishes itself through two primary technological pillars: the CRISPR/TARGATT genome editing platform and its GMP-grade induced pluripotent stem cell (iPSC) services. By providing these advanced tools, Applied Stemcell enables researchers and biopharmaceutical firms to streamline the development of novel therapeutics, effectively bridging the gap between laboratory discovery and clinical application. Its market position is defined by a commitment to precision medicine and the acceleration of complex biological workflows.
How much funding has Applied Stemcell raised?
Applied Stemcell has raised a total of $25M across 5 funding rounds:
Series B
$1.9M
Series C
$2.6M
Series D
$19M
Debt
$1M
Debt
$500K
Series B (2010): $1.9M, investors not publicly disclosed
Series C (2013): $2.6M, investors not publicly disclosed
Series D (2016): $19M supported by BioSciKin, Vi-Ventures, Hermed Capital, and Ping An Ventures
Debt (2020): $1M featuring PPP
Debt (2021): $500K backed by PPP
Key Investors in Applied Stemcell
BioSciKin
BioSciKin is an open platform for life science entrepreneurs that focuses on novel therapeutics, medical devices, and mobile healthcare services, providing R&D-oriented incubation and support.
Vi-Ventures
A boutique investment firm targeting TMT and healthcare technology sectors, specializing in assisting companies with international market expansion and cross-border growth.
Hermed Capital
A private investment firm that provides flexible working capital solutions and financial structuring to businesses, prioritizing common-sense decision-making over institutional bureaucracy.
What's next for Applied Stemcell?
With the support of its recent capital injection, Applied Stemcell is well-positioned to expand its manufacturing footprint and enhance its R&D infrastructure. The strategic focus will likely center on scaling its GMP-grade iPSC production to meet the increasing global demand for standardized cell therapy components. Furthermore, the company is expected to leverage its existing partnerships to deepen its penetration into international markets, particularly by facilitating cross-border collaborations in precision medicine. As the regulatory environment for gene editing continues to evolve, Applied Stemcell's emphasis on high-impact, scalable platforms will be instrumental in maintaining its competitive edge and driving long-term value for its stakeholders.
See full Applied Stemcell company page
